Imperial College London
Portrait Picture

Professor Thomas N Williams

Faculty of Medicine, Department of Surgery & Cancer

Chair in Haemoglobinopathy Research
 
 
 
//

Contact

 

tom.williams Website

 
 
//

Location

 

Norfolk PlaceSt Mary's Campus

//

Summary

 

Publications

Citation

BibTex format

@article{Silaba:2019:10.1016/S2214-109X(18)30491-1,
author = {Silaba, M and Ooko, M and Bottomley, C and Sande, C and Benamore, R and Park, K and Ignas, J and Maitland, K and Mturi, N and Makumi, A and Otiende, M and Kagwanja, S and Safari, S and Ochola, V and Bwanaali, T and Bauni, E and Gleeson, F and Deloria, Knoll M and Adetifa, I and Marsh, K and Williams, T and Kamau, T and Sharif, S and Levine, O and Hammitt, L and Scott, A},
doi = {10.1016/S2214-109X(18)30491-1},
journal = {The Lancet Global Health},
pages = {e337--e346},
title = {The impact of 10-valent Pneumococcal Conjugate Vaccine on theincidence of radiologically-confirmed pneumonia and clinically-definedpneumonia in Kenyan children: an interrupted time series analysis},
url = {http://dx.doi.org/10.1016/S2214-109X(18)30491-1},
volume = {7},
year = {2019}
}
Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - BackgroundPneumococcal conjugate vaccines (PCV) are highly protective against invasive pneumococcal disease caused by vaccine serotypes but the burden of pneumococcal disease in developing countries is dominated by pneumonia, most of which is non-bacteraemic. We examined the impact of 10-valent PCV on pneumonia incidence.MethodsWe linked prospective hospital surveillance for clinically-defined WHO severe or very-severe pneumonia at Kilifi County Hospital from 2002-2015 to population surveillance at Kilifi Health and Demographic Surveillance System, comprising 45,000 children aged <5 years. Chest radiographs were read according to a WHO standard. A 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PCV10) was introduced in Kenya in January 2011. In Kilifi, there was a 3-dose catch-up campaign for infants and a 2-dose catch-up campaign for children aged 1-4 years between January and March 2011. We estimated the impact of PCV10 on the incidence of clinically-defined and radiologically-confirmed pneumonia through interrupted time series analysis accounting for seasonal and temporal trends.FindingsAt the start of the study, in 2002/3, the incidence of admission with clinically-defined pneumonia was 21·7/1000/year in children aged 2-59 months. By the end of the catch-up campaign, 61·1% of children aged 2-11 months had received ≥2 doses and 62·3% of children aged 12-59 months had received ≥1 dose of PCV10. Across the whole 13-years of surveillance the incidence of clinically-defined pneumonia declined by 0.5% per month, independent of vaccine introduction; in contrast, there was no secular trend in the incidence of radiologically-confirmed pneumonia over 8 years of study.After adjusting for secular trend and season, incidence rate ratios for admission with radiologically-confirmed pneumonia, clinically-defined pneumonia, and diarrhoea (control condition), associated temporally with PCV10 introduction and th
AU  - Silaba,M
AU  - Ooko,M
AU  - Bottomley,C
AU  - Sande,C
AU  - Benamore,R
AU  - Park,K
AU  - Ignas,J
AU  - Maitland,K
AU  - Mturi,N
AU  - Makumi,A
AU  - Otiende,M
AU  - Kagwanja,S
AU  - Safari,S
AU  - Ochola,V
AU  - Bwanaali,T
AU  - Bauni,E
AU  - Gleeson,F
AU  - Deloria,Knoll M
AU  - Adetifa,I
AU  - Marsh,K
AU  - Williams,T
AU  - Kamau,T
AU  - Sharif,S
AU  - Levine,O
AU  - Hammitt,L
AU  - Scott,A
DO  - 10.1016/S2214-109X(18)30491-1
EP  - 346
PY  - 2019///
SN  - 2214-109X
SP  - 337
TI  - The impact of 10-valent Pneumococcal Conjugate Vaccine on theincidence of radiologically-confirmed pneumonia and clinically-definedpneumonia in Kenyan children: an interrupted time series analysis
T2  - The Lancet Global Health
UR  - http://dx.doi.org/10.1016/S2214-109X(18)30491-1
UR  - https://www.sciencedirect.com/science/article/pii/S2214109X18304911
UR  - http://hdl.handle.net/10044/1/65768
VL  - 7
ER  -
Download